CureVac SE

General information
CureVac SE
Friedrich-Miescher-Str. 15
72076 Tübingen, Baden-Württemberg

Contact person: Sarah Fakih, Vice President, Corporate Communications & IR
Company main phone: +49 (7071) 98830
Year founded:2000
Source of foundation:Spin-off from university
Name of foundation source:University of Tuebingen
No. of employees: Worldwide:  999
Corporate description / mission:
CureVac is a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”). The company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases.
State of ownership: Private / independent
Headquarters: HQ: Yes
IPO (year): 2020
Remarks on ownership / listings
CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S.
  • Biotechnology - Therapeutics and Diagnostics
  • Anti-infectives
  • Antibodies
  • Drug delivery
  • Immunotherapy
  • Nucleic acid drugs
  • Vaccines
Primary therapeutic areas:
  • Digestive system / gastroenterology
  • Diseases of the eye / ophthalmology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
Business model:
  • R&D
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:6
Phase II:5
Special IP situation:
The company currently has approximately 800 granted patents.
Technology used:
Financing details
Fiscal year (end of) 2023
Revenues:USD 56.97M
R&D expenses:USD 113.60M
Cash:USD 435.81M
Total liabilities:USD 293.80M
No. of shares:224'306'000
Market cap. / valuation:USD 731.24M
Collaborations & Clients
Partnering strategy / collaborations:
Bill & Melinda Gates Foundation
Coalition for Epidemic Preparedness Innovations (CEPI)
CRISPR Therapeutics, etc.